2326 GMT - The threat of U.S. tariffs could see protective-garment manufacturer Ansell face the re-emergence of uneven demand due to customer destocking, UBS analysts write in a note. They tell clients that they have become more optimistic about full-year sales growth at Ansell's healthcare unit, but that there are some risks ahead. They highlight the possibility that customers have built up inventory ahead of potential tariffs, which would eventually hit demand as they then use up the stock. Ansell needs to deliver on first-half analyst earnings expectations to continue recent support for its stock, the UBS note adds. UBS lifts its target price 12.5% to A$36.00 and keeps a buy rating on the stock, which is up 0.4% at A$30.63. (stuart.condie@wsj.com)
(END) Dow Jones Newswires
January 28, 2025 18:27 ET (23:27 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。